Michael Allison

Accuracy of FibroScan Controlled Attenuation Parameter and Liver Stiffness Measurement in Assessing Steatosis and Fibrosis in Patients With Nonalcoholic Fatty Liver Disease

Peter Eddowes, M. Sasso, Michael Allison et al. · Gastroenterology · 2019 · 1.3K citations · Full text

Hepatology, Liver Stiffness Measurement, Nonalcoholic Fatty Liver Disease +10

C3d of Complement as a Molecular Adjuvant: Bridging Innate and Acquired Immunity

Paul W. Dempsey, Michael Allison, Srinivas Akkaraju et al. · Science · 1996 · 1.2K citations

Bridging Innate, Adaptive Immune System, Innate Immune System +23

Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial

Zobair M. Younossi, Vlad Ratziu, Rohit Loomba et al. · The Lancet · 2019 · 1.2K citations · Full text

Interim Analysis, Metabolic Associated Steatohepatitis, Hepatology +7

NASH limits anti-tumour surveillance in immunotherapy-treated HCC

Dominik Pfister, Nicolás Gonzalo Núñez, Roser Pinyol et al. · Nature · 2021 · 1.2K citations · Full text

FibroScan-AST (FAST) score for the non-invasive identification of patients with non-alcoholic steatohepatitis with significant activity and fibrosis: a prospective derivation and global validation study

Philip N. Newsome, M. Sasso, Jonathan J Deeks et al. · ˜The œLancet. Gastroenterology & hepatology · 2020 · 729 citations · Full text